Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heavy metal containing doai
Patent
1992-11-25
1993-08-24
Prescott, Arthur C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heavy metal containing doai
556137, 548104, 548403, 548953, A61K 3128, C07F 1500
Patent
active
052389553
ABSTRACT:
Antitumor acting platinum(II or IV) complexes of the general formula ##STR1## where B represents a phenyl-C.sub.1 -C.sub.4 -alkyl radical which is optionally substituted in the phenyl nucleus by the radical R.sub.1 and R.sub.1 is hydrogen, halogen, trihalogen methyl, C.sub.1 -C.sub.6 -alkyl, hydroxy, C.sub.1 -C.sub.6 -alkoxy or C.sub.2 -C.sub.6 -alkanoyloxy or where B together with the structural part H.sub.2 N-CR.sub.2 < forms a tetrahydroisoquinoline radical, if B contains benzyl and R.sub.2 hydrogen and the benzyl radical in the 2-position contains the CH.sub.2 -radical or where B together with the structural part --CR.sub.2 < represents a tetrahydronaphthyl radical in which one CH.sub.2 group is optionally replaced by oxygen, or where B together with the structural part --CR.sub.2 < represents a decahydronaphthyl radical or an indanyl radical; R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 -alkyl, phenyl or phenyl-C.sub.1 -C.sub.4 -alkyl, it also being possible for the phenyl ring of this group R.sub.2 to be substituted by hydroxy, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -alkyl, C.sub.2 -C.sub.6 -alkanoyloxy or halogen; the radicals R.sub.3 and R.sub.4 are the same or different and represent hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.3 -C.sub.8 -cycloalkyl and X stands for the equivalent of a physiologically acceptable anion or X can also be a water molecule, where in the latter case the missing negative charge is saturated by a corresponding physiologically acceptable acid anion, where in the case of platinum(II) complexes, two of the groups X are absent.
REFERENCES:
patent: 4372890 (1983-02-01), Yoshikumi et al.
patent: 4845124 (1989-07-01), Kidani et al.
patent: 4921984 (1990-05-01), Nonatari et al.
patent: 5028727 (1991-07-01), Verbeek et al.
patent: 5034553 (1991-07-01), Verbeek et al.
Article entitled "Evidence of Delayed Internal . . . " by S. Morgan et al. in the Journal of Amer. Chem. Soc. vol. 109 No. 10, pp. 3151-3154 1987 (May 13, 1987).
Article entitled "Synthesis and Characterization of a New Quinquedentate . . . " by Kanda et al.; vol. 56, No. 11 Bull. Chem. Soc. Jpn., 56, 1983 (the chemical society of Japan) pp. 3268-3271.
Article entitled "Synthesis and Antitumor Activity . . . " by Brunner, et al. Nov. 30, 1989 Chemische Berichte pp. 1029-1038.
Chemical Abstracts Nov. 21, 1988 vol. 109 No. 21, 1988 p. 690.
Article entitled "Synthesis and Antitumor activity . . . " by Brunner et al. Eur. J. Med. Chem. (1990) 25,35-44.
Brunner Henri
Engel Jurgen
Hankofer Peter
Hilgard Peter
Maiterth Friedrich
Asta Pharma AG
Prescott Arthur C.
LandOfFree
Ethylene-substituted phenylalkylethylenediamine-platinum (II or does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ethylene-substituted phenylalkylethylenediamine-platinum (II or , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ethylene-substituted phenylalkylethylenediamine-platinum (II or will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-829536